| Gleevec/Glivec |
All Financial Data in US $ (mln) |
| Word Search (Top 10 - by date) |
Novartis Achieves Record Results in 2009 as Momentum from Recently Launched Products Drives Growth Across Its Entire Healthcare Portfolio
Novartis
(January 26, 2010)
|
CytRx to Conduct Phase 2 Clinical Trial with Bafetinib in B-cell Chronic Lymphocytic Leukemia
CytRx
(January 13, 2010)
|
Synta Presents Results at AACR-IASLC Demonstrating Potent and Synergistic Activity of STA-9090 in NSCLC Cell Lines Including Mutated EGFR, HER2, and KRAS
Synta Pharmaceuticals
(January 12, 2010)
|
Synta Pharmaceuticals Initiates Phase 2 Clinical Trial of STA-9090 in Gastrointestinal Stromal Tumors (GIST) following failure of Gleevec® and Sutent®
Synta Pharmaceuticals
(December 23, 2009)
|
Synta Pharmaceuticals Initiates Phase 2 Clinical Trial of STA-9090 in Non-Small Cell Lung Cancer
Synta Pharmaceuticals
(December 17, 2009)
|
EpiCept Provides Clinical and Business Update on Ceplene Program
EpiCept
(December 15, 2009)
|
Novartis Set to Sustain Its Leading Global Position in Oncology With Portfolio Targeting Various Tumors and Life-threatening Diseases
Novartis
(December 09, 2009)
|
Novartis Tasigna® Trial Shows Superior Results to Glivec® in Patients With Early-stage Chronic Myeloid Leukemia
Novartis
(December 08, 2009)
|
Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765
Pharmacyclics
(December 07, 2009)
|
ARIAD Presents Positive Clinical Proof-of-Concept Data on AP24534 in Drug-Resistant Hematological Cancers at ASH Annual Meeting
ARIAD Pharmaceuticals
(December 07, 2009)
|
|
|
|
|
EvaluatePharma® - the premier source for pharma and biotech analysis.
Expert integration of financial and product data across historic and forecast timeframes (1986 to 2014) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.
|
| Summary Product Name Information |
|
|
| Product Sales Summary 2006/07 |
|
Annual Sales WW - Sales
|
Growth per Year (%)
|
|
Rank1 |
Generic Name
|
Therapeutic Subcategory
|
2006 |
2007
|
2007 |
| Gleevec/Glivec2 |
|
|
|
2,554 |
3,050 |
|
+19% |
|
|
Note: Shaded Cells3 |
|
|
More Product Information for EvaluatePharma® subscribersSubscribers see:
- Sales (historic and forecast to 2014 where available) listed by the reporting company or companies, including royalty, license and JV revenue where applicable
- Details of all events impacting the product
- Detailed product information, including sales forecasts listed by the reporting company or companies, indications (approved and in trial)
|
Register to access more FREE content:
- 2008 Product Sales analysis
- Download analysis into Excel
- Search 2 yrs of company press releases
|
|
|
|